Telitacicept Wins China NMPA Nod for IgA Nephropathy
The conditional approval marks a regulatory milestone for dual cytokine inhibition in a kidney disease with limited the…
The conditional approval marks a regulatory milestone for dual cytokine inhibition in a kidney disease with limited the…
New findings from Psych Congress Elevate underscore neurological symptom management advances, a space adjacent to emerg…
The underserved patient segment represents an estimated $4 billion annual market opportunity, according to the company.
Immunosuppression mechanism under scrutiny as transplant tolerance data edges closer to clinical relevance for metaboli…
The gut-health biologics pipeline inches forward as a vedolizumab biosimilar clears a key regulatory milestone — with i…
The gut-targeted integrin inhibitor category draws biosimilar competition as regulators advance interchangeability revi…
The BLA acceptance marks a regulatory milestone for the gut-inflammation biologics pipeline, with biosimilar competitio…
Hepatocyte-directed vesicle technology positions the delivery platform at the intersection of pharma and advanced nutra…
Results published simultaneously in NEJM and Nature Medicine signal a new mechanistic benchmark for metabolic-health fo…
With BHB blends flooding e-commerce channels, operators and formulators face mounting pressure to substantiate ketone-d…
As the men's wellness segment expands, operators and formulators face tightening expectations around evidence-based pos…
Early-phase data presented at EULAR 2026 positions B-cell depletion as a credible mechanism in autoimmune disease manag…